Series B - AdvanCell
Investment Firm
Overview
AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
Announced Date
Aug 23, 2022
Funding Type
Series B
Highlights
Location
Sydney, New South Wales, Australia, Oceania
Social
Participant Investors
1
| Investor Name |
|---|
Round Details and Background
AdvanCell raised $12457610 on 2022-08-23 in Series B
AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
Company Funding History
2
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Aug 23, 2022 |  Series B - AdvanCell | 1 | - | 12.5M |
| Dec 23, 2021 | Grant - AdvanCell | 1 | - | 2.1M |
Recent Activity
There is no recent news or activity for this profile.